Last 12 months
Inside the activity.
9 purchase rows · 1 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 4 | 1 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 4 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2024 Filed May 14, 2024 21:57 UTC |
POLAN MARY LAKE PH DDirector
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 82 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059822 · ownership.xml · derivative · entry 5 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 82 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:57 UTC |
POLAN MARY LAKE PH DDirector
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059822 · ownership.xml · derivative · entry 4 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:57 UTC |
POLAN MARY LAKE PH DDirector
|
GrantCommon Stock | 82 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059822 · ownership.xml · nonDerivative · entry 2 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,040 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:57 UTC |
POLAN MARY LAKE PH DDirector
|
GrantCommon Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059822 · ownership.xml · nonDerivative · entry 1 POLAN MARY LAKE PH D · CIK 0001187716 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,958 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:55 UTC |
Michael Edward L.Director
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 106 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059820 · ownership.xml · derivative · entry 4 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 106 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:55 UTC |
Michael Edward L.Director
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 356 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059820 · ownership.xml · derivative · entry 3 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 356 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. F3 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating non-employee directors and occurred according to the elected deferred schedule. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:55 UTC |
Michael Edward L.Director
|
GrantCommon Stock | 106 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059820 · ownership.xml · nonDerivative · entry 2 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,286 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| May 12, 2024 Filed May 14, 2024 21:55 UTC |
Michael Edward L.Director
|
GrantCommon Stock | 356 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-059820 · ownership.xml · nonDerivative · entry 1 Michael Edward L. · CIK 0001391823 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,180 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:43 UTC |
Brandy LouiseSVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 1,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-050704 · ownership.xml · derivative · entry 3 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,918 Underlying: Common Stock · 1,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 1,459 shares vested on April 26, 2024; 1,459 shares will vest on April 26, 2025; and 1,459 shares will vest on April 26, 2026. F4 · derivative.expiration_date: 1,459 shares vested on April 26, 2024; 1,459 shares will vest on April 26, 2025; and 1,459 shares will vest on April 26, 2026. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:43 UTC |
Brandy LouiseSVP, Chief Information Officer
|
Tax withholdingCommon Stock | 538 | $39.64 | $21,326.32 |
DisclosureSEC source: 0000950170-24-050704 · ownership.xml · nonDerivative · entry 2 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,154 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| April 26, 2024 Filed Apr 30, 2024 21:43 UTC |
Brandy LouiseSVP, Chief Information Officer
|
GrantCommon Stock | 1,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-050704 · ownership.xml · nonDerivative · entry 1 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,692 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 22:18 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 9,041 | $0.00 Strike: $21.07 | $0.00 |
DisclosureSEC source: 0000950170-24-044893 · ownership.xml · derivative · entry 2 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,041 shares Expires 2024-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option award vested in full on May 6, 2015. Read SEC document |
| April 12, 2024 Filed Apr 16, 2024 22:18 UTC |
BUECHLER KENNETH FDirector
|
Exercise / conversionCommon Stock | 9,041 | $21.07 | $190,493.87 |
DisclosureSEC source: 0000950170-24-044893 · ownership.xml · nonDerivative · entry 1 BUECHLER KENNETH F · CIK 0001238916 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,679 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Bujarski Robert JosephInterim President, EVP & COO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039665 · ownership.xml · derivative · entry 3 Bujarski Robert Joseph · CIK 0001333458 · Interim President, EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,850 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F4 · derivative.expiration_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Bujarski Robert JosephInterim President, EVP & COO
|
Tax withholdingCommon Stock | 2,805 | $47.94 | $134,471.70 |
DisclosureSEC source: 0000950170-24-039665 · ownership.xml · nonDerivative · entry 2 Bujarski Robert Joseph · CIK 0001333458 · Interim President, EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,500 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Bujarski Robert JosephInterim President, EVP & COO
|
GrantCommon Stock | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039665 · ownership.xml · nonDerivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · Interim President, EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,305 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:59 UTC |
Busky Joseph M.Chief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039666 · ownership.xml · derivative · entry 4 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,850 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F5 · derivative.expiration_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:59 UTC |
Busky Joseph M.Chief Financial Officer
|
Tax withholdingCommon Stock | 2,234 | $47.94 | $107,097.96 |
DisclosureSEC source: 0000950170-24-039666 · ownership.xml · nonDerivative · entry 2 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,839 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:59 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantCommon Stock | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039666 · ownership.xml · nonDerivative · entry 1 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,073 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. F2 · balance_after: The amount of shares beneficially owned following this transaction includes an additional 202 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Kroll WernerSVP, Research & Development
|
Exercise / conversionRestricted Stock Units · Derivative | 3,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039664 · ownership.xml · derivative · entry 3 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,622 Underlying: Common Stock · 3,811 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 3,811 shares vested on March 28, 2024; the remaining 7,622 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F4 · derivative.expiration_date: 3,811 shares vested on March 28, 2024; the remaining 7,622 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Kroll WernerSVP, Research & Development
|
Tax withholdingCommon Stock | 1,801 | $47.94 | $86,339.94 |
DisclosureSEC source: 0000950170-24-039664 · ownership.xml · nonDerivative · entry 2 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,781 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:58 UTC |
Kroll WernerSVP, Research & Development
|
GrantCommon Stock | 3,811 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039664 · ownership.xml · nonDerivative · entry 1 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,582 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:57 UTC |
Hodges Michelle ASVP, General Counsel
|
Exercise / conversionRestricted Stock Units · Derivative | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039663 · ownership.xml · derivative · entry 3 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,926 Underlying: Common Stock · 2,462 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 2,462 shares vested on March 28, 2024; the remaining 4,926 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F4 · derivative.expiration_date: 2,462 shares vested on March 28, 2024; the remaining 4,926 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:57 UTC |
Hodges Michelle ASVP, General Counsel
|
Tax withholdingCommon Stock | 879 | $47.94 | $42,139.26 |
DisclosureSEC source: 0000950170-24-039663 · ownership.xml · nonDerivative · entry 2 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,441 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 19:57 UTC |
Hodges Michelle ASVP, General Counsel
|
GrantCommon Stock | 2,462 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039663 · ownership.xml · nonDerivative · entry 1 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,320 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC |
Iskra Michael S.Interim CEO, EVP & CCO
|
Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,850 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F5 · derivative.expiration_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC |
Iskra Michael S.Interim CEO, EVP & CCO
|
Tax withholdingCommon Stock | 1,773 | $47.94 | $84,997.62 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,350 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC |
Iskra Michael S.Interim CEO, EVP & CCO
|
GrantCommon Stock | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,123 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. F2 · balance_after: The amount of shares beneficially owned following this transaction includes an additional 291 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:07 UTC |
Bujarski Robert JosephInterim President, EVP & COO
|
GrantRestricted Stock Units · Derivative | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023249 · ownership.xml · derivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · Interim President, EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 Underlying: Common Stock · 21,367 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 21,367 shares will fully vest on June 30, 2025. F2 · derivative.expiration_date: 21,367 shares will fully vest on June 30, 2025. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:08 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023250 · ownership.xml · derivative · entry 1 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 Underlying: Common Stock · 21,367 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 21,367 shares will fully vest on June 30, 2025. F2 · derivative.expiration_date: 21,367 shares will fully vest on June 30, 2025. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:08 UTC |
Iskra Michael S.Interim CEO, EVP & CCO
|
GrantRestricted Stock Units · Derivative | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023253 · ownership.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 Underlying: Common Stock · 21,367 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 21,367 shares will fully vest on June 30, 2025. F2 · derivative.expiration_date: 21,367 shares will fully vest on June 30, 2025. Read SEC document |
| February 23, 2024 Filed Feb 26, 2024 18:48 UTC |
Busky Joseph M.Chief Financial Officer
|
PurchaseCommon Stock | 2,150 | $46.36 | $99,663.25 |
DisclosureSEC source: 0000950170-24-020435 · ownership.xml · nonDerivative · entry 1 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 2,150 F1 · price: The weighted average purchase price of these transactions was $46.3550 per share, with a range of $46.3205 to $46.3850 per share. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:07 UTC |
Brandy LouiseSVP, Chief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 473 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016352 · ownership.xml · derivative · entry 3 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 947 Underlying: Common Stock · 473 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 473 shares vested on February 14, 2024; 473 shares will vest on February 14, 2025; and 474 shares will vest on February 14, 2026. F5 · derivative.expiration_date: 473 shares vested on February 14, 2024; 473 shares will vest on February 14, 2025; and 474 shares will vest on February 14, 2026. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 21:07 UTC |
Brandy LouiseSVP, Chief Information Officer
|
Tax withholdingCommon Stock | 194 | $45.27 | $8,782.38 |
DisclosureSEC source: 0000950170-24-016352 · ownership.xml · nonDerivative · entry 2 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,233 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
Exercise / conversionRestricted Stock Units (Premium) · Derivative | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · derivative · entry 6 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 315 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
Exercise / conversionRestricted Stock Units (Converted) · Derivative | 1,052 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · derivative · entry 5 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,052 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. F4 · derivative.expiration_date: Release of restricted stock units was deferred pursuant to QuidelOrtho's deferred compensation program applicable to participating employees and occurred according to the elected deferred schedule. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
Tax withholdingCommon Stock | 180 | $68.15 | $12,267.00 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · nonDerivative · entry 4 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,380 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
GrantCommon Stock | 315 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · nonDerivative · entry 3 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,560 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
Tax withholdingCommon Stock | 575 | $68.15 | $39,186.25 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · nonDerivative · entry 2 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,245 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 19:50 UTC |
Bujarski Robert JosephEVP & COO
|
GrantCommon Stock | 1,052 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014858 · ownership.xml · nonDerivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,820 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:44 UTC |
BRYANT DOUGLAS CDirector · President & CEO
|
GrantRestricted Stock Units · Derivative | 46,254 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014149 · ownership.xml · derivative · entry 1 BRYANT DOUGLAS C · CIK 0001406652 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,254 Underlying: Common Stock · 46,254 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 46,254 shares will vest in equal installments on February 8, 2025, February 8, 2026 and February 8, 2027. F2 · derivative.expiration_date: 46,254 shares will vest in equal installments on February 8, 2025, February 8, 2026 and February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:43 UTC |
Bujarski Robert JosephEVP & COO
|
GrantRestricted Stock Units · Derivative | 17,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014147 · ownership.xml · derivative · entry 1 Bujarski Robert Joseph · CIK 0001333458 · EVP & COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,905 Underlying: Common Stock · 17,905 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. F2 · derivative.expiration_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:45 UTC |
Busky Joseph M.Chief Financial Officer
|
GrantRestricted Stock Units · Derivative | 17,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014152 · ownership.xml · derivative · entry 1 Busky Joseph M · CIK 0001385091 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,905 Underlying: Common Stock · 17,905 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. F2 · derivative.expiration_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:46 UTC |
Kroll WernerSVP, Research & Development
|
GrantRestricted Stock Units · Derivative | 14,920 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014153 · ownership.xml · derivative · entry 1 Kroll Werner · CIK 0001609320 · SVP, Research & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,920 Underlying: Common Stock · 14,920 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 9,946 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 4,974 shares will vest on February 8, 2027. F2 · derivative.expiration_date: 9,946 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 4,974 shares will vest on February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:42 UTC |
Hodges Michelle ASVP, General Counsel
|
GrantRestricted Stock Units · Derivative | 9,593 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014146 · ownership.xml · derivative · entry 2 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,593 Underlying: Common Stock · 9,593 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 3,197 shares will vest on February 8, 2025; the remaining 6,396 shares will vest in equal installments on February 8, 2026 and February 8, 2027. F1 · derivative.expiration_date: 3,197 shares will vest on February 8, 2025; the remaining 6,396 shares will vest in equal installments on February 8, 2026 and February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:42 UTC |
Hodges Michelle ASVP, General Counsel
|
GrantNon-Qualified Stock Option · Derivative | 9,593 | $0.00 Strike: $67.02 | $0.00 |
DisclosureSEC source: 0000950170-24-014146 · ownership.xml · derivative · entry 1 Hodges Michelle A. · CIK 0001833942 · SVP, General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,593 Underlying: Common Stock · 9,593 shares Expires 2034-02-08 F1 · derivative.exercise_date: 3,197 shares will vest on February 8, 2025; the remaining 6,396 shares will vest in equal installments on February 8, 2026 and February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:45 UTC |
Iskra Michael S.EVP & CCO
|
GrantRestricted Stock Units · Derivative | 17,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014151 · ownership.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,905 Underlying: Common Stock · 17,905 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. F2 · derivative.expiration_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:44 UTC |
Brandy LouiseSVP, Chief Information Officer
|
GrantRestricted Stock Units · Derivative | 5,756 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014150 · ownership.xml · derivative · entry 2 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,756 Underlying: Common Stock · 5,756 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F3 · derivative.exercise_date: 1,918 shares will vest on February 8, 2025; the remaining 3,838 shares will vest in equal installments on February 8, 2026 and February 8, 2027. F3 · derivative.expiration_date: 1,918 shares will vest on February 8, 2025; the remaining 3,838 shares will vest in equal installments on February 8, 2026 and February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:44 UTC |
Brandy LouiseSVP, Chief Information Officer
|
GrantNon-Qualified Stock Option · Derivative | 5,755 | $0.00 Strike: $67.02 | $0.00 |
DisclosureSEC source: 0000950170-24-014150 · ownership.xml · derivative · entry 1 Brandy Louise · CIK 0001978061 · SVP, Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,755 Underlying: Common Stock · 5,755 shares Expires 2034-02-08 F1 · derivative.exercise_date: 3,836 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining1,919 shares will vest on February 8, 2027. Read SEC document |
| February 08, 2024 Filed Feb 13, 2024 02:43 UTC |
Klein PatrickChief Administrative Officer
|
GrantRestricted Stock Units · Derivative | 9,593 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014148 · ownership.xml · derivative · entry 2 Klein Patrick · CIK 0001978037 · Chief Administrative Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,593 Underlying: Common Stock · 9,593 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 3,197 shares will vest on February 8, 2025; the remaining 6,396 shares will vest in equal installments on February 8, 2026 and February 8, 2027. F1 · derivative.expiration_date: 3,197 shares will vest on February 8, 2025; the remaining 6,396 shares will vest in equal installments on February 8, 2026 and February 8, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.